Inoperable Clinical Trials

1 recruitingLast updated: May 5, 2026

There are 11 actively recruiting inoperable clinical trials across 25 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Goyang-si, South Korea, Madrid, Spain, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Inoperable Trials at a Glance

11 actively recruiting trials for inoperable are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Goyang-si, Madrid, and Barcelona. Lead sponsors running inoperable studies include AstraZeneca, Anhui Provincial Hospital, and H. Lee Moffitt Cancer Center and Research Institute.

Browse inoperable trials by phase

Treatments under study

About Inoperable Clinical Trials

Looking for clinical trials for Inoperable? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Inoperable trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Inoperable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 1Phase 2

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled31 locationsNCT04802759
Recruiting
Phase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Melanoma Stage IVInoperable DiseaseMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute29 enrolled1 locationNCT04562129
Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 1Phase 2

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Inoperable Locally Advanced HER2-Negative Breast CancerMetastatic HER2-Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd180 enrolled1 locationNCT06942234
Recruiting
Phase 2

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital37 enrolled1 locationNCT06422858
Recruiting
Phase 2

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Lung CancerInoperable Disease
Second Affiliated Hospital of Guangzhou Medical University90 enrolled1 locationNCT06483347
Recruiting
Not Applicable

Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy

Rectal CancerComorbidities and Coexisting ConditionsBrachytherapy+1 more
Sir Mortimer B. Davis - Jewish General Hospital45 enrolled1 locationNCT04336202
Recruiting

Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer

Esophageal Squamous Cell CarcinomaChemoradiotherapyInitial Inoperable
Anhui Provincial Hospital97 enrolled1 locationNCT06190847
Recruiting

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell CarcinomaChemoradiotherapyImmunonutrition+1 more
Anhui Provincial Hospital70 enrolled1 locationNCT05833594
Recruiting

Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma.

Patients with locally advanced inoperable pancreatic adenocarcinoma
Southern Adelaide Local Health Network15 enrolled3 locationsACTRN12613001013752